Skip to main content

Table 1 Duration of burst activity

From: The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

Treatment Group 1 month Post-MPTP 2 months Post-MPTP 3 months Post-MPTP
Placebo 0.4 ± 0.322 29.5 ± 28.323 2.2 ± 0.776
2.5 mg/kg pioglitazone 0.4 ± 0.196 0.8 ± 0.385 0.6 ± 0.22
5 mg/kg pioglitazone 0.6 ± 0.21 0.9 ± 0.437 0.5 ± 0.409
  1. Two months following MPTP administration, placebo-treated monkeys showed an increase in the duration of burst activity (expressed as the mean ± SEM of the ratio baseline/post period) compared to baseline. Due to individual differences repeated measures ANOVA; failed to find a significant effect of time (P = 0.195), treatment (P = 0.213) or effect of time × treatment (P = 0.270).